

COPPADIS-2015: an ongoing global Parkinson's disease project about disease progression with more than 700 patients included. Preliminary results of baseline evaluations.

D. Santos¹, S. Escalante², E. Cubo³, F. Carrillo⁴, J-C. Martínez Castrillo⁵, P. Sánchez Alonso⁶, M. Gemma A. Losada⁷, N. López Aríztegui⁸, M. Itziar Gastón⁹, J. Kulisevsky¹⁰, M. Menéndez González¹¹, M. Seijo¹², J. Ruíz Martínez¹³, C. Valero¹⁴, M. Kurtis¹⁵, B. Galeano¹⁶, O. De Fábregues-Boixar¹⁷, J. González Ardura¹⁸, C. Prieto¹⁹, P. Martínez Martín²⁰, COPPADIS Study Group²¹

¹Neurology, Hospital Arquitecto Marcide y Hospital Naval, Complejo Hospitalario Universitario de Ferrol (CHUF), Spain

²Neurology, Hospital de Tortosa Verge de la Cinta (HTVC), Spain

³Neurology, Complejo Asistencial Universitario de Burgos, Spain

⁴Neurology, Hospital Universitario de Canarias, San Cristóbal de la Laguna, Spain

⁵Neurology, Hospital Universitario Ramón y Cajal, Spain

⁶Neurology, Hospital Universitario Puerta de Hierro, Spain

⁷Neurology, Hospital Álvaro Cunqueiro, Complejo Hospitalario Universitario de Vigo (CHUVI), Spain

⁸Neurology, Complejo Hospitalario de Toledo, Spain

⁹Neurology, Complejo Hospitalario de Navarra, Spain

¹⁰Neurology, Hospital de Sant Pau, Spain

¹¹Neurology, Hospital Universitario Central de Asturias, Spain

¹²Neurology, Complejo Hospitalario Universitario de Pontevedra (CHOP), Spain

¹³Neurology, Hospital Universitario Donostia, Spain

¹⁴Neurology, Hospital Arnau de Vilanova, Spain

¹⁵Neurology, Hospital Ruber Internacional, Spain

¹⁶Neurology, Hospital Universitario de Ceuta, Spain

¹⁷Neurology, Hospital Universitario Vall d'Hebron, Spain

¹⁸Neurology, Hospital Universitario Lucus Augusti (HULA), Spain

¹⁹Neurology, Hospital Rey Juan Carlos, Spain

²⁰Centro Nacional de Epidemiología y CIBERNED, Instituto de Salud Carlos III, Spain

²¹Neurology, Other Centres from Spain, Spain

Background and objective: To describe preliminary results of baseline evaluations of a Spanish ongoing global Parkinson's disease (PD) Project, COPPADIS-2015 (Cohort of Patient's with Parkinson's Disease in Spain, 2015). **Methods:** Observational, descriptive, non-interventional, 5-year follow-up, national (Spain), multicenter, evaluation study (Santos-Garcia D et al. BMC Neurol 2016;16:26). PD patients, principal caregivers and controls will be assessed in detail during follow-up. Here, we presented general preliminary results about baseline visits. **Results:** A total of 717 PD patients (59.8% males; 62.8 ± 9 years old), 302 caregivers and 209 controls (49.5% males; 61.2 ± 8.5 years old) were included in the study between January, 2016 and October, 2017. The mean disease duration was 5.5 ± 4.4 years. Hoehn&Yahr stage was 1 or 2 in 88.9% (Unified Parkinson's Disease Rating Scale-part III 22.7 ± 11.5) of the patients while 28.1% and 17.5% of them presented with motor fluctuations and dyskinesias, respectively. Mean Non-Motor Symptoms Scale (NMSS) total score was 45.5 ± 38 and 25.9% of the patients presented cognitive impairment, 14.1% major depression, 19.8% impulse control disorder and 56.5% pain. Compared to the control group, PD patients presented a significant higher burden of non-motor symptoms and a worse quality of life. More than 340 subjects have undergone complementary studies (serum biomarkers, genetic and neuroimaging) so far. **Conclusions:** COPPADIS-2015 would have to provide important knowledge about PD progression. Currently, we have extensive information about the baseline visits (cross-sectional study) that will be analyzed in detail in the short-term future.